Table 1.
Baseline Characteristics of Participants
| Designated male at birth (n = 92) | Designated female at birth (n = 194) | |
|---|---|---|
| Age, median (interquartile range), y* | 17.3 (16.2, 18.6) | 16.2 (15.1, 17.5) |
| Affirmed Gender, n (%)* | ||
| Male | 0 (0%) | 78 (40%) |
| Female | 36 (39%) | 0 (0%) |
| Transgender Female (male-to-female) | 51 (55%) | 0 (0%) |
| Transgender Male (female-to-male) | 0 (0%) | 103 (53%) |
| Gender Fluid | 0 (0%) | 2 (1%) |
| Gender Queer | 1 (1%) | 1 (0.5%) |
| Non-binary | 4 (4%) | 10 (5%) |
| Race/Ethnicity, n (%) | ||
| White | 59 (64%) | 111 (57%) |
| Black or African American | 2 (2%) | 5 (3%) |
| Multi-Race | 11 (12%) | 20 (10%) |
| Asian, Native Hawaiian, or Pacific Islander | 2 (2%) | 8 (4%) |
| Hispanic / Latino, Non-White | 16 (16%) | 31 (16%) |
| Hispanic / Latino, White | 2 (2%) | 19 (10%) |
| Other | 1 (1%) | 0 (0%) |
| Tanner Stage at Baseline Visit, n (%) * | ||
| III | 3 (4%) | 1 (0.5%) |
| IV | 10 (12%) | 17 (9%) |
| V | 73 (85%) | 164 (90%) |
| Height at Baseline Visit, mean (SD), cm* | 173.4 (7.6) | 163.1 (6.7) |
| Weight at Baseline Visit, median (interquartile range), kg* | 67.2 (59.4, 80.5) | 61.9 (54.7, 73.2) |
| Body Mass Index at Baseline Visit, median (interquartile range), kg/m2* | 22.2 (20.1, 25.8) | 23.5 (20.6, 28.1) |
| Estrogen Type, n (%)** | ||
| Oral | 77 (84%) | - |
| Transdermal | 12 (13%) | - |
| Intramuscular | 3 (3%) | - |
| Estradiol Dose, median (interquartile range)*** | ||
| Oral administration, mg/day | 4 (2–4) | |
| Transdermal administration, mg/day | 0.5 (0.25–0.1) | |
| Intramuscular, mg/week | 15 (10–15) | |
| Testosterone Type, n (%)** | ||
| Subcutaneous | - | 189 (97%) |
| Transdermal gel | - | 5 (3%) |
| Testosterone Dose, median (interquartile range)*** | ||
| Subcutaneous administration, mg/week | 40 (26–50) | |
| Transdermal administration, mg/day | 40.5 (25–50) | |
| Using spironolactone, n (%) * | 58 (63%) | 1 (0.5%) |
*
p < 0.05 for difference between designated sex
**
Anticipated formulation at time of baseline visit
***
Calculated over 24-month study period